4 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow KRAS Gene Mutation: new trials by email Literature Review of KRAS Gene Mutation trials Research Report on KRAS Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance] - Solid Tumors, NSCLC | Phase 1 / Phase 2 | Completed | Calithera Biosciences, Inc | 53 | 2019-06-25 | 2022-09-19 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Cardiff Oncology | 68 | 2019-06-24 | 2025-03-04 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG - Non Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2018-10-09 | 2025-05-16 |
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Methotrexate, Pharmacokinetic Study, Regorafenib - KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Completed | Stanford University | 22 | 2018-08-14 | 2023-08-01 |
Carcinoma, Non-Small-Cell Lung (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Bevacizumab (1) · CB-839 (1) · IFL protocol (1) · Methotrexate (1) · Pharmacogenomic Variants (1) · Tablets (1) · merphos (1) · onvansertib (1) · palbociclib (1) · ponatinib (1) · regorafenib (1) · trametinib (1)
Calithera Biosciences, Inc (1) · Cardiff Oncology (1) · Memorial Sloan Kettering Cancer Center (1) · Stanford University (1)
United States (4)
Emil Kuriakose, MD (1) · Heather Wakelee (1) · Kathryn Arbour, MD (1)